Concepedia

Susan Feyerabend

SF

Statistics

Publications

52

Citations

7.6K

H-Index

29

Active since

2006

Affiliations

Institut Gustave Roussy(Current)

Institute of Cancer Research

Royal Marsden Hospital

University of Tübingen

Merck & Co., Inc., Rahway, NJ, USA (United States)

Susan Feyerabend is an author at Institut Gustave Roussy specializing in oncology, medicine, and prostate cancer.

ORCID

Publications per year

2006–2025

52

Publications

52

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +15

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · The Lancet Oncology · 2019 · 813 citations · Full text

, , +16

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 706 citations · Full text

, , +17

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Ronald de Wit, Johann S. de Bono, Cora N. Sternberg et al. · New England Journal of Medicine · 2019 · 660 citations · Full text

, , +17

Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy

Alexander Haese, Alexandre de la Taille, Hendrik Van Poppel et al. · European Urology · 2008 · 451 citations

, , +11

1–5 of 52